id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10075 R46632 |
Coste (Carbamazepine), 2020 | Diagnosis Mental retardation (F70–F79) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick | Adjustment: No | 0.57 [0.03;9.75] C | 0/176 10/2,108 | 10 | 176 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7279 R46629 |
Kasradze (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2017 | Full scale IQ (WPPSI-4) (mean age 4-4.5 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) |
0.18 [0.02;1.80] excluded (control group) |
-/16 -/3 | - | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5496 R46630 |
Kasradze (Carbamazepine) (Controls unexposed, disease free), 2017 | Full scale IQ (WPPSI-4) (mean age 4-4.5 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) Matched | 5.75 [1.98;16.71] | -/16 -/50 | - | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8042 R46628 |
Deshmukh (Carbamazepine), 2016 | Vineland-II Adaptative Behavior Scales - Low and moderately low in the overall ABC (Adaptative Behavior Composite) | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 1.46 [0.24;9.03] | 5/97 3/104 | 8 | 97 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S386 R46631 |
Meador (Carbamazepine), 2013 | IQ <85 (DAS) (at 4.5 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 1.40 [0.42;4.59] C | 6/54 6/73 | 12 | 54 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6941 R46626 |
Cummings (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Mild or significant delay (score ≥1, <2 SD or ≥2 SD below the mean) (Bayley Scales of Infant Development or the Griffiths Scale) (mean age in years: m1=3.0 and m0=2.7) | throughout pregnancy | retrospective cohort (registry) | exposed to other treatment, sick excluded | Adjustment: No |
8.72 [1.06;71.65] C excluded (control group) |
10/49 1/35 | 11 | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6939 R46627 |
Cummings (Carbamazepine) (Controls unexposed, disease free), 2011 | Mild or significant delay (score ≥1, <2 SD or ≥2 SD below the mean) (Bayley Scales of Infant Development or the Griffiths Scale) (mean age in years: m1=3.0 and m0=4.3) | throughout pregnancy | retrospective cohort (registry) | unexposed, disease free | Adjustment: Yes | 7.70 [1.40;43.10] | 10/49 2/44 | 12 | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 2.74 [1.17;6.42] | 42 | 392 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, disease free; 3: Carbamazepine; 4: Carbamazepine; 5: Carbamazepine) (Controls unexposed, disease free;
Asymetry test p-value = 0.4781 (by Egger's regression)
slope=2.1445 (1.3990); intercept=-1.5204 (1.8810); t=0.8083; p=0.4781
excluded 6941, 7279